FDA Approves Onswik: A Once-Weekly Insulin for Type 2 Diabetes Management
The U.S. Food and Drug Administration (FDA) has granted approval for Onswik (insulin efsitora alfa-gobe) injection, a long-acting insulin analog intended to assist adults with type 2 diabetes mellitus in managing their blood glucose levels. This medication is to be used as an adjunct to diet and exercise, and it is administered via subcutaneous injection once a week on the same day each week. However, it is important to note that Onswik is not recommended for individuals with type 1 diabetes mellitus due to an increased risk of severe hypoglycemia, which is a dangerously low level of blood sugar. With this approval, Onswik becomes the second once-weekly insulin option available for adults living with type 2 diabetes.
Type 2 diabetes mellitus is characterized by elevated blood glucose levels resulting from the body's inability to produce sufficient insulin or effectively utilize the insulin it produces. Insulin plays a crucial role in regulating blood glucose by facilitating the movement of glucose from the bloodstream into cells and decreasing the liver's glucose production. Onswik is designed to provide a long-acting insulin effect that helps lower blood glucose levels over a weekly dosing interval.
The effectiveness of Onswik was evaluated in four randomized, open-label, active-controlled studies involving adults with type 2 diabetes. These studies included participants who had not previously used insulin, those who had been treated with once- or twice-daily basal insulin, and individuals who had received both basal and mealtime insulin. Throughout the trials, Onswik was administered once weekly and compared with once-daily insulin glargine or insulin degludec, while participants continued their other diabetes treatments, including mealtime insulin.
Results from the studies indicated that Onswik effectively reduced hemoglobin A1c levels, which reflect average blood glucose levels over time, to a similar degree as insulin glargine and insulin degludec.
Common adverse reactions associated with Onswik include hypoglycemia, hypersensitivity reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain. Hypoglycemia is notably the most frequently reported adverse reaction linked to insulin use, including Onswik, with severe cases potentially leading to seizures, unconsciousness, or life-threatening complications. The labeling for Onswik includes warnings and precautions regarding medication errors, accidental overdose, hypersensitivity reactions, hypokalemia, and fluid retention, particularly when used with certain medications.
For further details on the risks associated with Onswik, refer to the full prescribing information provided by the FDA.




